A nurse is caring for a client with eclampsia who is receiving magnesium sulfate intravenously.

Which of the following findings indicates magnesium toxicity?

A. To prevent seizures.

Magnesium sulfate is a mineral that can reduce seizure risks in women with severe preeclampsia.It is often given intravenously and can also be used to prolong pregnancy for up to two days.Magnesium sulfate is also used to prevent and manage seizures in women with postpartum preeclampsia.

• Statement B is wrong because magnesium sulfate does not lower blood pressure.It may be given along with medications that help reduce blood pressure.

• Statement C is wrong because magnesium sulfate does not induce labor.It may be given to delay delivery for up to 48 hours to allow time for the administration of drugs that speed up the baby’s lung development.

• Statement D is wrong because magnesium sulfate does not reduce edema.Edema is a common symptom of preeclampsia, but it is not a direct cause of complications.

To increase placental perfusion.

Hydralazine is an antihypertensive drug that dilates the blood vessels and lowers the blood pressure.By doing so, it improves the blood flow to the placenta and reduces the risk of fetal hypoxia and growth restriction.

Choice A is wrong because hydralazine does not prevent cerebral edema.

Cerebral edema is a complication of severe preeclampsia or eclampsia that can cause seizures, headaches, and visual disturbances.Hydralazine may lower the blood pressure and reduce the risk of stroke, but it does not directly affect the brain swelling.

Choice B is wrong because hydralazine does not reduce uterine contractions.

Uterine contractions are stimulated by oxytocin and prostaglandins, which are not affected by hydralazine.Hydralazine may cause reflex tachycardia, which can increase the cardiac output and uterine blood flow, but it does not alter the uterine muscle activity.

Choice D is wrong because hydralazine does not promote diuresis.

Diuresis is the increased production of urine by the kidneys.

Hydralazine may cause fluid retention and edema by activating the renin-angiotensin-aldosterone system, which increases sodium and water reabsorption.Hydralazine may also cause a decrease in renal perfusion and glomerular filtration rate, which can impair the kidney function and urine output.